View Webinar Slide Deck
Join us for a discussion with FDA on their direct-to-consumer prescription drug advertising final rule which becomes effective on May 20th, establishing new standards required for conveying information in a “major statement” relating to the applicable drug’s major side effects and contraindications in a “clear, conspicuous, and neutral manner” (CCN).
Speakers
Suzanna Boyle – Regulatory Council, Office of Medical Policy, OPDP @ U.S. Food and Drug Administration
James Potter – Executive Director @ CHC
CHC Summary on FDA DTC Prescription Drug Advertising Final Rule
FDA Education Resources